PL414457A1 - New cellular line carcinoma mucoepidermale and its application for in vitro tests - Google Patents

New cellular line carcinoma mucoepidermale and its application for in vitro tests

Info

Publication number
PL414457A1
PL414457A1 PL414457A PL41445715A PL414457A1 PL 414457 A1 PL414457 A1 PL 414457A1 PL 414457 A PL414457 A PL 414457A PL 41445715 A PL41445715 A PL 41445715A PL 414457 A1 PL414457 A1 PL 414457A1
Authority
PL
Poland
Prior art keywords
application
vitro tests
mucoepidermale
new cellular
cellular line
Prior art date
Application number
PL414457A
Other languages
Polish (pl)
Other versions
PL229507B1 (en
Inventor
Małgorzata Jarmuż-Szymczak
Joanna Janiszewska
Maciej Giefing
Magdalena Kostrzewska-Poczekaj
Małgorzata Wierzbicka
Hanna Piotrowska-Kempisty
Jadwiga Jodynis-Liebert
Andrzej Marszałek
Magdalena Bodnar
Original Assignee
Instytut Genetyki Człowieka Polskiej Akademii Nauk
Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Genetyki Człowieka Polskiej Akademii Nauk, Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu filed Critical Instytut Genetyki Człowieka Polskiej Akademii Nauk
Priority to PL414457A priority Critical patent/PL229507B1/en
Publication of PL414457A1 publication Critical patent/PL414457A1/en
Publication of PL229507B1 publication Critical patent/PL229507B1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest nowa wyizolowana linia komórkowa, pochodząca z komórek guza ślinianki z rozpoznaniem histopatologicznym raka śluzowo - naskórkowego, wykorzystywana do badań in vitro m.in. do przeprowadzania wyciszania lub indukcji ekspresji genów, analiz funkcjonalnych określających żywotność zmodyfikowanych komórek, analiz cytotoksyczności nanokompleksów połączonych z przeciwciałem do określonych białek.The subject of the application is a new isolated cell line derived from salivary gland tumor cells with histopathological diagnosis of muco-epidermal cancer, used for in vitro tests, including for silencing or inducing gene expression, functional analyzes determining the viability of modified cells, cytotoxicity analyzes of nanocomplexes linked to the antibody to specific proteins.

PL414457A 2015-10-22 2015-10-22 New cellular line carcinoma mucoepidermale and its application for in vitro tests PL229507B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL414457A PL229507B1 (en) 2015-10-22 2015-10-22 New cellular line carcinoma mucoepidermale and its application for in vitro tests

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL414457A PL229507B1 (en) 2015-10-22 2015-10-22 New cellular line carcinoma mucoepidermale and its application for in vitro tests

Publications (2)

Publication Number Publication Date
PL414457A1 true PL414457A1 (en) 2017-04-24
PL229507B1 PL229507B1 (en) 2018-07-31

Family

ID=58672062

Family Applications (1)

Application Number Title Priority Date Filing Date
PL414457A PL229507B1 (en) 2015-10-22 2015-10-22 New cellular line carcinoma mucoepidermale and its application for in vitro tests

Country Status (1)

Country Link
PL (1) PL229507B1 (en)

Also Published As

Publication number Publication date
PL229507B1 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CL2021000704A1 (en) Signal Regulatory Alpha Protein Antibodies and Methods of Use. (application divisional 668-2019)
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
CL2018003758A1 (en) Anti-dll3-antibody antibody conjugates and methods of use. (divisional application 201800458)
MX2020013169A (en) Camptothecin conjugates.
MX2017012352A (en) Constructs targeting afp peptide/mhc complexes and uses thereof.
CL2015000582A1 (en) Anti-mcam antibodies and associated methods of use
BR112016014022A2 (en) anti-cd3 antibodies, isolated nucleic acid, vector, host cell, anti-cd3 antibody production method, immunoconjugate, composition, use of anti-cd3 antibody, treatment methods, methods of enhancing immune function and kit
CO6721041A2 (en) Anti-pcsk9 antibody and methods of use
EA201690617A1 (en) COMBINING ANTI-LAG-3-ANTIBODIES AND ANTI-PD-1-ANTIBODIES FOR THE TREATMENT OF TUMORS
TR201904270T4 (en) Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions.
EA202192126A3 (en) METHODS FOR COLLECTING MAMMALIAN CULTURES
UY35964A (en) HUMAN ANTIBODIES FOR PD? 1
MX2017014056A (en) Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof.
ECSP13013022A (en) FGFR1 AGONISTS AND THEIR METHODS OF USE
CR20150247A (en) ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE
CR20140382A (en) ANTI-LRP5 ANTIBODIES AND METHODS OF USE
EA201500172A1 (en) MODIFIED POLYPEPTIDES OF THE FACTOR X AND THEIR APPLICATION
CU24405B1 (en) CRY1DA1 AMINO ACID SEQUENCE VARIATIONS PROTEINS FOR LEPIDOPTERS
CL2019002323A1 (en) Il-13ra2 antibody and its use.
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
ES2721935T3 (en) Anti-BAG3 antibodies for therapeutic use
TWD180565S (en) Applicator
MX2016005854A (en) Neuregulin allosteric anti-her3 antibody.
AR112602A1 (en) ANTI-TrkB ANTIBODIES
AR088245A1 (en) CHARACTERIZATION OF PROTEIN AND THE CHO-MIF GENE AND USE OF THE SAME